Mitsubishi UFJ Trust & Banking Corp Boosts Stock Holdings in Moderna, Inc. $MRNA

Mitsubishi UFJ Trust & Banking Corp grew its position in shares of Moderna, Inc. (NASDAQ:MRNA) by 58.5% during the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 144,283 shares of the company’s stock after buying an additional 53,273 shares during the quarter. Mitsubishi UFJ Trust & Banking Corp’s holdings in Moderna were worth $4,255,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other institutional investors have also recently made changes to their positions in the company. M&T Bank Corp grew its holdings in shares of Moderna by 36.4% during the fourth quarter. M&T Bank Corp now owns 24,958 shares of the company’s stock valued at $736,000 after buying an additional 6,660 shares during the last quarter. Pictet Asset Management Holding SA boosted its holdings in Moderna by 0.5% in the fourth quarter. Pictet Asset Management Holding SA now owns 738,094 shares of the company’s stock worth $22,870,000 after purchasing an additional 3,605 shares during the last quarter. Sanctuary Advisors LLC boosted its holdings in Moderna by 21.9% in the fourth quarter. Sanctuary Advisors LLC now owns 14,088 shares of the company’s stock worth $415,000 after purchasing an additional 2,529 shares during the last quarter. Vanguard Group Inc. boosted its holdings in Moderna by 1.0% in the fourth quarter. Vanguard Group Inc. now owns 41,584,782 shares of the company’s stock worth $1,226,335,000 after purchasing an additional 399,487 shares during the last quarter. Finally, Universal Beteiligungs und Servicegesellschaft mbH boosted its holdings in Moderna by 8.1% in the fourth quarter. Universal Beteiligungs und Servicegesellschaft mbH now owns 86,358 shares of the company’s stock worth $2,698,000 after purchasing an additional 6,459 shares during the last quarter. Hedge funds and other institutional investors own 75.33% of the company’s stock.

More Moderna News

Here are the key news stories impacting Moderna this week:

• Positive Sentiment: Q1 revenue sharply exceeded estimates — $389M (+~260% YoY) driven by strong international COVID?19 vaccine sales, showing demand outside the U.S. and a meaningful top?line rebound. Article Title
• Positive Sentiment: Pipeline and upcoming regulatory catalysts remain market drivers — the mRNA?1010 seasonal flu PDUFA (Aug. 5) and advancing oncology programs give upside optionality beyond COVID vaccines. Article Title
• Neutral Sentiment: Company reiterated 2026 outlook (up to ~10% revenue growth) and signaled continued operating expense reductions excluding the non?recurring settlement — suggests management expects sustainable margin improvements over time. Article Title
• Neutral Sentiment: Revenue concentration shifted heavily to ex?U.S. markets (~80% of Q1 revenue), which helped the beat but increases sensitivity to international procurement cycles and government deals. Article Title
• Negative Sentiment: A $0.9B one?time litigation settlement was recorded in Q1, producing a wider GAAP loss (GAAP EPS of $(3.40)) and negative gross/net margins — this sizable charge weighed on the earnings print despite the revenue beat. Article Title
• Negative Sentiment: Stock reaction was volatile — shares initially rallied on the revenue beat but later moved lower as investors digested the settlement, continued unprofitability, and reliance on a few government contracts. Article Title

Wall Street Analyst Weigh In

Several equities research analysts recently issued reports on the stock. Piper Sandler raised their target price on shares of Moderna from $63.00 to $69.00 and gave the stock an “overweight” rating in a report on Monday, February 23rd. Leerink Partners restated an “underperform” rating on shares of Moderna in a report on Friday, January 30th. BMO Capital Markets upgraded shares of Moderna from a “market perform” rating to a “buy” rating in a report on Monday, January 12th. Morgan Stanley set a $33.00 target price on shares of Moderna in a report on Friday. Finally, Barclays raised their target price on shares of Moderna from $25.00 to $48.00 and gave the stock an “equal weight” rating in a report on Thursday, April 2nd. Two investment analysts have rated the stock with a Buy rating, twelve have assigned a Hold rating and five have issued a Sell rating to the stock. According to data from MarketBeat, the company presently has a consensus rating of “Reduce” and a consensus target price of $34.60.

Insider Buying and Selling at Moderna

In other news, President Stephen Hoge sold 160,009 shares of Moderna stock in a transaction on Monday, February 23rd. The shares were sold at an average price of $48.84, for a total transaction of $7,814,839.56. Following the transaction, the president owned 1,457,427 shares in the company, valued at $71,180,734.68. This trade represents a 9.89% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. 10.80% of the stock is owned by corporate insiders.

Moderna Stock Performance

Shares of Moderna stock opened at $45.37 on Monday. The company’s fifty day simple moving average is $51.84 and its 200-day simple moving average is $39.47. The stock has a market capitalization of $17.92 billion, a PE ratio of -5.57 and a beta of 1.05. Moderna, Inc. has a 1-year low of $22.28 and a 1-year high of $59.55. The company has a debt-to-equity ratio of 0.08, a current ratio of 2.41 and a quick ratio of 2.35.

Moderna (NASDAQ:MRNA) last issued its quarterly earnings results on Friday, May 1st. The company reported ($3.40) earnings per share for the quarter, missing the consensus estimate of ($3.02) by ($0.38). The business had revenue of $389.00 million for the quarter, compared to analysts’ expectations of $236.37 million. Moderna had a negative return on equity of 26.64% and a negative net margin of 143.55%.The company’s revenue was up 260.2% compared to the same quarter last year. During the same quarter in the prior year, the business earned ($2.52) EPS. As a group, equities analysts anticipate that Moderna, Inc. will post -8 earnings per share for the current year.

Moderna Company Profile

Moderna, Inc is a biotechnology company headquartered in Cambridge, Massachusetts, specializing in messenger RNA (mRNA) therapeutics and vaccines. The company’s platform leverages synthetic mRNA to instruct cells to produce proteins that can prevent or treat diseases. Since its founding in 2010, Moderna has advanced from early-stage research into a broad pipeline of vaccine and therapeutic candidates designed to address infectious diseases, rare genetic disorders and chronic illnesses.

Moderna’s flagship product is its mRNA-based COVID-19 vaccine, which was the first of its kind to receive emergency use authorization and later full approval in multiple jurisdictions.